Literature DB >> 28738377

Updated Nasal Surgery for Obstructive Sleep Apnea.

David M Johnson, Ryan J Soose.   

Abstract

Numerous studies report that difficulty breathing through the nose is associated with reduced sleep quality, increased daytime dysfunction, and increased risk of snoring and obstructive sleep apnea (OSA). Additionally, chronic nasal obstruction often complicates and limits successful medical device therapy for OSA, particularly with continuous positive airway pressure (CPAP). When medical evaluation and management of the nose is inadequate, surgical therapy to lower nasal resistance has been shown to substantially improve sleep and breathing outcome measures. Although nasal surgery in isolation does not have a consistent effect on the apnea-hypopnea index in OSA patients, it does have robust evidence on improving snoring, subjective sleep quality, daytime sleepiness, sleep-related quality of life measures, and other important OSA outcome measures. Furthermore, in OSA patients with sinonasal disease who are struggling with CPAP and other medical devices, sinonasal surgery also has the potential to lower pressure requirements and improve adherence rates. Nasal surgery plays a key adjunctive role in the management of an OSA patient population.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28738377     DOI: 10.1159/000470868

Source DB:  PubMed          Journal:  Adv Otorhinolaryngol        ISSN: 0065-3071


  2 in total

1.  Analyses of aerodynamic characteristics of the oropharynx applying CBCT: obstructive sleep apnea patients versus control subjects.

Authors:  Hui Chen; Yingguang Li; Johan Hc Reiber; Jan de Lange; Shengxian Tu; Paul van der Stelt; Frank Lobbezoo; Ghizlane Aarab
Journal:  Dentomaxillofac Radiol       Date:  2018-01-02       Impact factor: 2.419

2.  Adult sleep apnea and tonsil hypertrophy: should pharyngoplasty be associated with tonsillectomy?

Authors:  Robin Baudouin; Marc Blumen; Cyril Chaufton; Frédéric Chabolle
Journal:  Sleep Breath       Date:  2019-05-21       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.